Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To evaluate the efficacy and safety of intravitreal aflibercept injection (IAI) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Ophthalmology

Title: Ophthalmology

ISSN (Electronic): 1549-4713

ISSN (Print): 0161-6420

Publication date (Electronic): Jul 2014

Volume: 121

Issue: 7

Affiliations

[1 ] Ophthalmic Consultants of Boston, Boston, Massachusetts.

[2 ] Palmetto Retina Center, West Columbia, South Carolina.

[3 ] Retina-Vitreous Associates Medical Group, Beverly Hills, California.

[4 ] Retina Consultants of Houston, The Methodist Hospital, Houston, Texas.

[5 ] Regeneron Pharmaceuticals, Inc., Tarrytown, New York.

[6 ] Bayer HealthCare, Berlin, Germany; Department of Neurology, University of Erlangen-Nürnberg, Erlangen, Germany.

[7 ] Bayer HealthCare, Berlin, Germany; Klinik und Poliklinik fur Augenheilkunde, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany.

[8 ] Bayer HealthCare, Berlin, Germany; Department of Neurology, Heinrich-Heine-Universitat, Dusseldorf, Germany.

[9 ] Wills Eye Hospital, Philadelphia, Pennsylvania. Electronic address: jhaller@willseye.org.

Article

Publisher Item ID: S0161-6420(14)00071-2

DOI: 10.1016/j.ophtha.2014.01.027

PubMed ID: 24679444

SO-VID: 79db6370-a5e6-4ffd-b1aa-0442d112420b

History

Data availability:

Comments

Comment on this article

scite_

Cited by 81

See all cited by